Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. We currently have one Phase 3 ready program, A-002, and two Phase 2 clinical programs, A-623 and A-001.

A-002 and A-001 inhibit a novel enzyme target known as secretory phospholipase A2, or sPLA2. Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease.

A-623 targets elevated levels of B-lymphocyte stimulator, or BLyS (also known as BAFF), which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple sclerosis, Sjögren's Syndrome, Graves' Disease and others.

Late Stage Clinical Pipeline

A-002 Oral sPLA2	Acute Coronary Syndrome (Cardiovascular Disease)		more
A-623 Anti-BLyS/BAFF	Systemic Lupus Erythematosus (Autoimmune Disease)		more
A-001 IV sPLA2	Acute Chest Syndrome (Sickle Cell Disease)		more
A-003 Novel sPLA2	Multiple Indications		more